TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Cardiologists make case against routine interventions for asymptomatic severe AS
Aortic valve replacement is likely inevitable for patients with asymptomatic severe aortic stenosis. Immediately performing TAVR or SAVR, however, may not always be the answer.
So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients
Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.
AHA still working to find more patients with severe aortic stenosis who may require care
The initiative is designed to help identify more patients who may require aortic valve replacement. Brian Lindman, MD, provided an update on the project's efforts.

Permanent pacemaker implantation after TAVR does not increase risk of death or heart failure

Prior studies have suggested that TAVR patients could face worse outcomes if they require a permanent pacemaker.

TAVR safe and effective for patients with cirrhosis

Patients with cirrhosis of the liver often undergo TAVR at a younger age, but the outcomes remain strong.

Just 3.6% of TAVR procedures in the US performed by women

In addition, researchers noted, there were no female specialists performing TAVR in 19 states.

TAVR and SAVR deliver similar 5-year outcomes for CKD patients

“The choice of intervention in patients with CKD and aortic stenosis is complex and influenced by multiple competing factors," researchers said.

Next-day discharge after TAVR is safe and effective, new meta-analysis confirms

Researchers tracked data from six different studies, focusing on the likelihood of potential issues such as bleeding and vascular complications.

TAVR provides comparable value for low-risk patients with bicuspid and tricuspid AS

Researchers examined data from more than 3,000 TAVR procedures performed with balloon-expandable valves.

Surgical explantation after TAVR failure: What cardiologists, and patients, should know

Redo TAVR is not always a feasible treatment option, researchers explained. TAVR explantation can be offered to a larger patient population.

Valve-in-valve TAVR a safe alternative for patients with failed bioprosthetic valves

The final decision between ViV TAVR and repeat SAVR, researchers said, should be based on multiple factors.

Around the web

Radiology Business

The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business

Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

TAVR

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Cardiologists make case against routine interventions for asymptomatic severe AS

So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients

AHA still working to find more patients with severe aortic stenosis who may require care

Around the web